The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

POHANKA Michal KAŇOVSKÝ Petr BAREŠ Martin PULKRÁBEK Jiří REKTOR Ivan

Year of publication 2005
Type Article in Periodical
Magazine / Source Parkinsonism and Related Disorders
MU Faculty or unit

Faculty of Medicine

Citation
Field Neurology, neurosurgery, neurosciences
Keywords Parkinson disease; pergolid; sexual dysfunction
Description Fourteen male patients suffering from Parkinson's disease, each of whom had been treated with L-DOPA, and in whom additional treatment with oral dopamine agonist (DA) was needed, were followed for a period of one year. Pergolide mesylate was given to each patient, and titrated to a total daily dose of 3 mg. All of the patients were taking L-DOPA. The assessments consisted of neurological examination, unified Parkinson's disease rating scale (UPDRS) III and IV subscales scoring, mini mental state examination (MMSE) scoring, the neuropsychological examination, biochemical and hematological examinations and a sexological examination during which the patients filled-in the international index of erectile function (IIEF) questionnaire. Pergolide mesylate significantly improved all sexual functions in younger male Parkinsonian patients who were still interested in sexual activities.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.